In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.
Yours faithfully,
Darren Keamy
Company Secretary
CLINUVEL PHARMACEUTICALS LTD
Level 11, 535 Bourke Street, Melbourne, Victoria 3000, Australia
www.clinuvel.com
CLINUVEL PHARMACEUTICALS LIMITED
2020 Annual General Meeting
Wednesday, 11 November 2020
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details
Resolution
Resolution
Type
1
Adoption of Remuneration Report
Ordinary
2
Re-election of Mr Willem Blijdorp
Ordinary
3
Re-election of Prof Jeffrey Rosenfeld
Ordinary
Instructions given to validly appointed proxies
(as at proxy close)
For
Against
Proxy's
Abstain
Discretion
10,264,112
5,245,981
631,117
55,067
63.59%
32.50%
3.91%
18,136,623
1,606,096
631,117
29,479
89.02%
7.88%
3.10%
19,411,947
328,373
631,117
31,878
95.29%
1.61%
3.10%
Number of votes cast on the poll
(where applicable)
For
Against
Abstain*
10,660,678
5,828,731
62,567
64.65%
35.35%
18,662,480
2,203,204
36,979
89.44%
10.56%
20,541,742
329,043
31,878
98.42%
1.58%
Resolution
Result
Carried /
Not Carried
Carried
Carried
Carried
In relation to Resolution 1 - Adoption of Remuneration Report, as more than 25% of the votes were cast against this resolution, this constitutes a first strike for purposes of the Corporations Act 2001 (Cth).
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Clinuvel Pharmaceuticals Limited published this content on 12 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2020 22:40:02 UTC
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Companyâs pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
CLINUVEL PHARMACEUTICALS LIMITED 
